Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pertuzumab) in the context of the neoadjuvant I-SPY2 pha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e6340916dac6476fac8b24ed5afd32c1
record_format	dspace
spelling	oai:doaj.org-article:e6340916dac6476fac8b24ed5afd32c12021-11-08T11:09:06ZNeoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial10.1038/s41467-021-26019-y2041-1723https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c12021-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-26019-yhttps://doaj.org/toc/2041-1723HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pertuzumab) in the context of the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence.Amy S. ClarkChristina YauDenise M. WolfEmanuel F. PetricoinLaura J. van ‘t VeerDouglas YeeStacy L. MoulderAnne M. WallaceA. Jo ChienClaudine IsaacsJudy C. BougheyKathy S. AlbainKathleen KemmerBarbara B. HaleyHyo S. HanAndres Forero-TorresAnthony EliasJulie E. LangErin D. EllisRachel YungDebu TripathyRita NandaJulia D. WulfkuhleLamorna Brown-SwigartRosa I. GallagherTeresa HelstenErin RoeschCheryl A. EwingMichael AlvaradoErin P. CraneMeredith BuxtonJulia L. ClennellMelissa PaoloniSmita M. AsareAmy WilsonGillian L. HirstRuby SinghraoKatherine SteegAdam AsareJeffrey B. MatthewsScott BerryAshish SanilMichelle MeliskoJane PerlmutterHope S. RugoRichard B. SchwabW. Fraser SymmansNola M. HyltonDonald A. BerryLaura J. EssermanAngela M. DeMicheleNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Amy S. Clark Christina Yau Denise M. Wolf Emanuel F. Petricoin Laura J. van ‘t Veer Douglas Yee Stacy L. Moulder Anne M. Wallace A. Jo Chien Claudine Isaacs Judy C. Boughey Kathy S. Albain Kathleen Kemmer Barbara B. Haley Hyo S. Han Andres Forero-Torres Anthony Elias Julie E. Lang Erin D. Ellis Rachel Yung Debu Tripathy Rita Nanda Julia D. Wulfkuhle Lamorna Brown-Swigart Rosa I. Gallagher Teresa Helsten Erin Roesch Cheryl A. Ewing Michael Alvarado Erin P. Crane Meredith Buxton Julia L. Clennell Melissa Paoloni Smita M. Asare Amy Wilson Gillian L. Hirst Ruby Singhrao Katherine Steeg Adam Asare Jeffrey B. Matthews Scott Berry Ashish Sanil Michelle Melisko Jane Perlmutter Hope S. Rugo Richard B. Schwab W. Fraser Symmans Nola M. Hylton Donald A. Berry Laura J. Esserman Angela M. DeMichele Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
description	HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pertuzumab) in the context of the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence.
format	article
author	Amy S. Clark Christina Yau Denise M. Wolf Emanuel F. Petricoin Laura J. van ‘t Veer Douglas Yee Stacy L. Moulder Anne M. Wallace A. Jo Chien Claudine Isaacs Judy C. Boughey Kathy S. Albain Kathleen Kemmer Barbara B. Haley Hyo S. Han Andres Forero-Torres Anthony Elias Julie E. Lang Erin D. Ellis Rachel Yung Debu Tripathy Rita Nanda Julia D. Wulfkuhle Lamorna Brown-Swigart Rosa I. Gallagher Teresa Helsten Erin Roesch Cheryl A. Ewing Michael Alvarado Erin P. Crane Meredith Buxton Julia L. Clennell Melissa Paoloni Smita M. Asare Amy Wilson Gillian L. Hirst Ruby Singhrao Katherine Steeg Adam Asare Jeffrey B. Matthews Scott Berry Ashish Sanil Michelle Melisko Jane Perlmutter Hope S. Rugo Richard B. Schwab W. Fraser Symmans Nola M. Hylton Donald A. Berry Laura J. Esserman Angela M. DeMichele
author_facet	Amy S. Clark Christina Yau Denise M. Wolf Emanuel F. Petricoin Laura J. van ‘t Veer Douglas Yee Stacy L. Moulder Anne M. Wallace A. Jo Chien Claudine Isaacs Judy C. Boughey Kathy S. Albain Kathleen Kemmer Barbara B. Haley Hyo S. Han Andres Forero-Torres Anthony Elias Julie E. Lang Erin D. Ellis Rachel Yung Debu Tripathy Rita Nanda Julia D. Wulfkuhle Lamorna Brown-Swigart Rosa I. Gallagher Teresa Helsten Erin Roesch Cheryl A. Ewing Michael Alvarado Erin P. Crane Meredith Buxton Julia L. Clennell Melissa Paoloni Smita M. Asare Amy Wilson Gillian L. Hirst Ruby Singhrao Katherine Steeg Adam Asare Jeffrey B. Matthews Scott Berry Ashish Sanil Michelle Melisko Jane Perlmutter Hope S. Rugo Richard B. Schwab W. Fraser Symmans Nola M. Hylton Donald A. Berry Laura J. Esserman Angela M. DeMichele
author_sort	Amy S. Clark
title	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
title_short	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
title_full	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
title_fullStr	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
title_full_unstemmed	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
title_sort	neoadjuvant t-dm1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for her2+ breast cancer in the adaptively randomized i-spy2 trial
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
work_keys_str_mv	AT amysclark neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT christinayau neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT denisemwolf neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT emanuelfpetricoin neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT laurajvantveer neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT douglasyee neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT stacylmoulder neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT annemwallace neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT ajochien neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT claudineisaacs neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT judycboughey neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT kathysalbain neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT kathleenkemmer neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT barbarabhaley neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT hyoshan neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT andresforerotorres neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT anthonyelias neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT julieelang neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT erindellis neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT rachelyung neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT debutripathy neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT ritananda neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT juliadwulfkuhle neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT lamornabrownswigart neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT rosaigallagher neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT teresahelsten neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT erinroesch neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT cherylaewing neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT michaelalvarado neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT erinpcrane neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT meredithbuxton neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT julialclennell neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT melissapaoloni neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT smitamasare neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT amywilson neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT gillianlhirst neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT rubysinghrao neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT katherinesteeg neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT adamasare neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT jeffreybmatthews neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT scottberry neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT ashishsanil neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT michellemelisko neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT janeperlmutter neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT hopesrugo neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT richardbschwab neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT wfrasersymmans neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT nolamhylton neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT donaldaberry neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT laurajesserman neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial AT angelamdemichele neoadjuvanttdm1pertuzumabandpaclitaxeltrastuzumabpertuzumabforher2breastcancerintheadaptivelyrandomizedispy2trial
_version_	1718442385318346752

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Ejemplares similares